PCM
ALXN

Prelude Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Prelude Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-800
Closed -$92K – 2226
2020
Q3 		$92K Buy
+800
New +$86.3K ﹤0.01% 940
2019
Q2 		– Sell
-30,000
Closed -$4.05M – 2302
2019
Q1 		$4.05M Buy
+30,000
New +$3.73M 0.23% 75
2018
Q2 		– Sell
-3,000
Closed -$334K – 2059
2018
Q1 		$334K Buy
+3,000
New +$359K 0.02% 555

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Prelude Capital Management's ALXN Position: Q3 2021 in Review

Prelude Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 124,788 shares — an estimated $22.9M sold.

Prelude Capital Management first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $22.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Prelude Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Prelude Capital Management sold 124,788 Alexion Pharmaceuticals shares in Q3 2021, an estimated $22.9M.
  • Prelude Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Prelude Capital Management's Alexion Pharmaceuticals position peaked at $22.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Prelude Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.